Danaher: 2027 Growth Reacceleration Should Drive Upside (NYSE:DHR)
· seekingalpha.com
Danaher is a Buy, with revenue growth that may accelerate in 2027 as respiratory headwinds fade and bioprocessing rebounds. Read more on DHR stock here.
Danaher Corporation's ( DHR ) revenue growth should accelerate exiting this year and into the next year as the drag in respiratory business that it is currently...